[RFA-TR-25-002] Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed)

Description

Titolo: Preclinical Proof of Concept Studies for Rare Diseases (R21 Clinical Trial Not Allowed) Numero dell'opportunità: RFA-TR-25-002 Stato: aperto (posted) Tipo di opportunità: Discretionary Ente: National Institutes of Health — Department of Health and Human Services Tipo di finanziamento: Grant Categoria: Health Programma (ALN): 93.350 National Center for Advancing Translational Sciences Pubblicato il: 2024-12-06 Scadenza per le domande: 2027-07-02 Cofinanziamento richiesto: no Chi può fare domanda: State governments; Independent school districts; City or township governments; Special district governments; County governments; Native American tribal governments (Federally recognized); Others (see text field entitled "Additional Information on Eligibility" for clarification); Small businesses; Native American tribal organizations (other than Federally recognized tribal governments); Public and State controlled institutions of higher education; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; Private institutions of higher education; For profit organizations other than small businesses Altre condizioni di eleggibilità: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Descrizione: This notice of funding opportunity (NOFO) provides funding to conduct efficacy studies in an established rare disease preclinical model to demonstrate that a proposed therapeutic agent warrants further development. In addition to preclinical efficacy, accompanying pharmacodynamic and pharmacokinetic studies would be supported. Therapeutic agents include small molecules, biologics or biotechnology-derived products. The goal of this NOFO is to spur therapeutic development for a variety of rare diseases by advancing projects to the point where they would attract subsequent investment supporting full Investigational New Drug (IND) application development or progression to clinical trials in the case of repurposing or repositioning. Annuncio completo: http://grants.nih.gov/grants/guide/rfa-files/RFA-TR-25-002.html Contatto: [email protected]

Sectors

Source

Source: grants.gov